Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Modeyso (dordaviprone)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Jazz

Drug class:

AKT inhibitor, ERK inhibitor, DRD2 antagonist, ClpP agonist

Related drugs:

‹

›

H3.3K27M	Glioma	H3.3K27M	Glioma	dordaviprone Sensitive: B - Late Trials dordaviprone Sensitive : B	dordaviprone Sensitive: B - Late Trials dordaviprone Sensitive : B
H3.3K27M	Glioma	H3.3K27M	Glioma	bevacizumab + dordaviprone Sensitive: C3 – Early Trials bevacizumab + dordaviprone Sensitive : C3	bevacizumab + dordaviprone Sensitive: C3 – Early Trials bevacizumab + dordaviprone Sensitive : C3
EGFR overexpression	Glioblastoma	EGFR overexpression	Glioblastoma	dordaviprone Resistant: D – Preclinical dordaviprone Resistant : D	dordaviprone Resistant: D – Preclinical dordaviprone Resistant : D
AR splice variant 7	Prostate Cancer	AR splice variant 7	Prostate Cancer	darolutamide + dordaviprone Resistant: D – Preclinical darolutamide + dordaviprone Resistant : D	darolutamide + dordaviprone Resistant: D – Preclinical darolutamide + dordaviprone Resistant : D
KRAS G12D	Pancreatic Cancer	KRAS G12D	Pancreatic Cancer	dordaviprone Sensitive: D – Preclinical dordaviprone Sensitive : D	dordaviprone Sensitive: D – Preclinical dordaviprone Sensitive : D